Skip to main content

Advertisement

Figure 5 | Molecular Cancer

Figure 5

From: Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines

Figure 5

Effect of erlotinib and cetuximab combination on cell viability in NSCLC cell lines. Calu-3, H322 sensitive cells (A, B) and H1299 resistant cells (C) were exposed to the indicated concentrations of erlotinib for 96 h or cetuximab for 72 h and to erlotinib for 24 h followed by the combination of erlotinib and cetuximab for 72 h. After the treatments, cell viability was assessed by MTT assay. Data are expressed as percent inhibition of cell viability versus control cells and are mean values of three separate experiments (**Pā€‰<ā€‰0.01 ***Pā€‰<ā€‰0.001).

Back to article page